Evidence map›Paper›PMID 36314172›Full record

Trial reportAlimentary pharmacology & therapeutics2023

Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis.

Yu Kyung Cho, Jae Hak Kim, Hyun-Soo Kim, Tae-Oh Kim, Jung-Hwan Oh, Suck Chei Choi, Jeong Seop Moon, Sang Kil Lee, Sung Woo Jung, Sung Soo Kim and 19 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alimentary pharmacology & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06991348 (Multicenter, Active-controlled, Randomized, Double-blind, Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole), which is not on this map. Cited by 32 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 4 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06991348 phase4recruitingnot on this mapstarted 2024, after this paper: background citation

Multicenter, Active-controlled, Randomized, Double-blind, Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole: TOP-GERD

TypeinterventionalSponsorCarnot LaboratoriesRan2024 to 2025Enrolled128ConditionsGastroesophageal Reflux DiseaseArmsTegoprazan, Pantoprazole
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. [Drug Therapy for Gastroesophageal Reflux Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 20 institutions in 3 countries.

Yu Kyung ChoCatholic Photomedicine Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.ORCID 0000-0002-7297-6577
Jae Hak KimDepartment of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, South Korea.ORCID 0000-0001-6270-3703
Hyun-Soo KimDepartment of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Christian Hospital, Wonju, South Korea.ORCID 0000-0001-7190-0362
Tae-Oh KimDepartment of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, South Korea.ORCID 0000-0002-7359-1599
Jung-Hwan OhDepartment of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.ORCID 0000-0002-9274-882X
Suck Chei ChoiDepartment of Internal Medicine, Wonkwang University Hospital, Iksan, South Korea.ORCID 0000-0003-1338-3306
Jeong Seop MoonDepartment of Internal Medicine, Inje University, Seoul Paik Hospital, Seoul, South Korea.ORCID 0000-0002-5909-8159
Sang Kil LeeDepartment of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea.ORCID 0000-0002-0721-0364
Sung Woo JungDepartment of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.ORCID 0000-0003-1954-1678
Sung Soo KimDepartment of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, South Korea.ORCID 0000-0002-9831-0597
Hye-Kyung JungDepartment of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, South Korea.ORCID 0000-0002-6653-5214
Sang Pyo LeeDepartment of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, South Korea.ORCID 0000-0002-4495-3714
Gab-Jin CheonDepartment of Internal Medicine, GangNeung Asan Hospital, College of Medicine, Ulsan University, Gangneung, South Korea.
Moo In ParkDepartment of Internal Medicine, Kosin University College of Medicine, Busan, South Korea.ORCID 0000-0003-2071-6957
Hwoon-Yong JungDepartment of Gastroenterology, Asan Medical Center, University of Ulsan, Seoul, South Korea.ORCID 0000-0003-1281-5859
Kwang Hyun KoDigestive Disease Center, CHA Bundang Medical Center, CHA University, Seongnam, South Korea.ORCID 0000-0001-5168-1377
In Kyung SungDepartment of Internal Medicine, Konkuk University Medical Center, Seoul, South Korea.ORCID 0000-0002-3848-5571
Si Hyung LeeDepartment of Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea.ORCID 0000-0001-7221-7506
Ju Yup LeeDepartment of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea.ORCID 0000-0003-0021-5354
Soo Teik LeeDepartment of Internal Medicine, Jeonbuk National University Hospital, Jeonju, South Korea.ORCID 0000-0002-0758-1923
Poong-Lyul RheeDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea.ORCID 0000-0003-0495-5296
Nayoung KimDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam and Seoul National University College of Medicine, Seoul, South Korea.ORCID 0000-0002-9397-0406
Su Jin HongDepartment of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea.ORCID 0000-0003-2012-0360
Hyun Jin KimDepartment of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon, South Korea.
Gwang Ha KimDepartment of Internal Medicine, Pusan National University College of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.ORCID 0000-0001-9721-5734
Kwang Jae LeeDepartment of Gastroenterology, Ajou University Hospital, Ajou University School of Medicine, Suwon, South Korea.ORCID 0000-0002-8534-0850
Sung Kook KimDepartment of Internal Medicine, Kyungpook National University Hospital, Daegu, South Korea.ORCID 0000-0002-2861-8123
Woon Geon ShinDepartment of Internal Medicine, Hallym University College of Medicine/Institute for Liver and Digestive Diseases, Chuncheon, South Korea.ORCID 0000-0002-9851-5576
Oh Young LeeDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul, South Korea.ORCID 0000-0002-6025-530X
Severance Hospital · KRChangwon National University · KREwha Womans University · KRKyungpook National University Hospital · KRAjou University Hospital · KRCHA University Bundang Medical Center · KRDongguk University Ilsan Hospital · KRGangneung Asan Hospital · KRHallym University · KRHanyang University · KRInje University Haeundae Paik Hospital · KRInje University Seoul Paik Hospital · KRKeimyung University · KRKonkuk University Medical Center · KRKorea University · KRKosin University · KRPusan National University Hospital · KRSamsung Medical Center · KRSeoul National University Bundang Hospital · KRSoonchunhyang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTegoprazan is a novel potassium-competitive acid blocker used to treat acid-related disorders.

aimTo compare tegoprazan 25 mg with lansoprazole 15 mg as maintenance therapy in healed erosive oesophagitis (EE)

methodsIn this phase 3, double-blind, multi-centre study, patients with endoscopically confirmed healed EE were randomised 1:1 to receive tegoprazan 25 mg or lansoprazole 15 mg once daily for up to 24 weeks. The primary efficacy endpoint was the endoscopic remission rate after 24 weeks. The secondary efficacy endpoint was the endoscopic remission rate after 12 weeks. Safety endpoints included adverse events, clinical laboratory results and serum gastrin and pepsinogen I/II levels.

resultsWe randomised patients to tegoprazan 25 mg (n = 174) or lansoprazole 15 mg (n = 177). Most had mild EE (Los Angeles (LA) grade A: 57.3%, LA grade B: 37.3%). The endoscopic remission rate after 24 weeks was 90.6% with tegoprazan and 89.5% with lansoprazole. Tegoprazan was not inferior to lansoprazole for maintaining endoscopic remission at 24 weeks and 12 weeks. In subgroup analysis, tegoprazan 25 mg showed no significant difference in maintenance rate according to LA grade (p = 0.47). The maintenance effect of tegoprazan was consistent in CYP2C19 extensive metabolisers (p = 0.76). Increases in serum gastrin were not higher in tegoprazan-treated than lansoprazole-treated patients.

conclusionsTegoprazan 25 mg was non-inferior to lansoprazole 15 mg in maintenance of healing of mild EE. In this study, tegoprazan had a similar safety profile to lansoprazole.

Indexed as

GastrinsHumansLansoprazoleGastrinsLansoprazole

Identifiers

PMID36314172
PMCPMC10092320
OpenAlexW4307776684

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.